Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Trading 03-28 12:20:42 EDT

18.41

-0.38

-2.02%

High18.82	Low18.27	Vol220.59K
Open18.82	D1 Closing18.79	Amplitude2.93%
Mkt Cap3.13B	Tradable Cap1.32B	Total Shares169.86M
T/O4.07M	T/O Rate0.31%	Tradable Shares71.86M
P/B8.87	ROE-74.17%	EPS-2.62
52wk High34.47	52wk Low17.01	P/E-7.04
Dividend0.00	Div.Yield0.00	ROA-44.73%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":18.41,"timestamp":1743178834956,"preClose":18.79,"halted":0,"volume":220427,"delay":0,"floatShares":71855162,"shares":169860683,"eps":-2.615248,"marketStatus":"Trading","change":-0.38,"latestTime":"03-28 12:20:35 EDT","open":18.82,"high":18.82,"low":18.27,"amount":4066337.2221419998,"amplitude":0.029271,"askPrice":18.42,"askSize":15,"bidPrice":18.38,"bidSize":147,"shortable":3,"etf":0,"ttmEps":-2.615248,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":18.79,"preHourTrading":{"tag":"盘前","latestPrice":18.79,"preClose":18.79,"latestTime":"09:29 EDT","volume":252,"amount":4729.080132,"timestamp":1743168599999},"postHourTrading":{"tag":"盘后","latestPrice":18.91,"preClose":18.79,"latestTime":"17:33 EDT","volume":23129,"amount":434788.926,"timestamp":1743111195651},"volumeRatio":0.231768,"impliedVol":0.3898,"impliedVolPercentile":0.208},"requestUrl":"/m/hq/s/IMVT","defaultTab":"news","newsList":[{"id":"2522860768","title":"Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522860768","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522860768?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:12","pubTimestamp":1742926370,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Roivant Sciences Ltd.  stands against other best stocks to buy according to billionaire David Einhorn.David Einhorn is a highly regarded hedge fund manager, who co-foundedGreenlight Capitalin 1996. Einhorn shot to fame after he correctly forecasted the collapse of Lehman Brothers during the financial crisis. He graduated from Cornell University and garnered his skills in the hedge fund industry under the mentorship of Gary Siegler and Peter Collery at the SC Fundamental Value Fund.Due to his prowess in long/short equity strategies, David Einhorn is being tagged as one of the most successful hedge fund managers.To list the 10 Best Stocks to Buy According to Billionaire David Einhorn, we selected the top 10 stocks in Greenlight Capital’s portfolio as per its Q4 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roivant-sciences-ltd-nasdaq-roiv-181250568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4139","SQQQ","TSYW.SI","BK4112","IE00BKPKM429.USD","IE00B3QW5Z07.USD","QID","GLRE","NVIW.SI","LU2210149790.SGD","QLD","IE00BGHQF748.EUR","PSQ","BK4588","IE00B64PRP62.GBP","USJW.SI","BK4019","LU2210150020.SGD","TQQQ","ROIV","NDAQ","LU2095319765.USD","MNQmain","IMVT","BK4007","USAW.SI",".IXIC","NQmain"],"gpt_icon":1},{"id":"2521946101","title":"BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2521946101","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521946101?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 00:44","pubTimestamp":1742489055,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate** Immunovant IMVT.O said on Wednesday its experimental treatment, batoclimab, for a type of chronic ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL4N3Q318R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","IMVT"],"gpt_icon":0},{"id":"2521461259","title":"Buy Rating Affirmed for IMVT-1402: Promising Study Results and Strategic Focus in FcRn Space","url":"https://stock-news.laohu8.com/highlight/detail?id=2521461259","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521461259?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 00:25","pubTimestamp":1742487929,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Alex Thompson CFA from St...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-imvt-1402-promising-study-results-and-strategic-focus-in-fcrn-space?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-imvt-1402-promising-study-results-and-strategic-focus-in-fcrn-space?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"gpt_icon":0},{"id":"2521461815","title":"IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2521461815","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521461815?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 22:19","pubTimestamp":1742480340,"startTime":"0","endTime":"0","summary":"Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis  and initial results from Period 1 of a mid-stage study of the same candidate for chronic inflammatory demyelinating polyneuropathy .IMVT’s Batoclimab Shows Superior Efficacy in MG Patients. The phase III study is evaluating the efficacy and safety of batoclimab in adult patients with moderate to severe MG. Per the data readout, the study met its primary endpoint of mean change from baseline in the MG Activities of Daily Living  score, used to determine the impact of weekly or bi-monthly doses of batoclimab, in acetylcholine receptor antibody positive  patients after 12 weeks.Immunovant reported that MG patients who received the weekly680mg subcutaneous dose of batoclimab achieved a 5.6-point improvement in MG-ADL and a 4.7-point improvement was observed in patients receiving the 340mg dose compared to a 3.6-point improvement in the placebo group at week 1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imvt-unlikely-pursue-batoclimab-mg-141900033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BZ1G4Q59.USD","DVAX","LU0109394709.USD","BK4550","LU1066051498.USD","LU2468319806.SGD","IE00B19Z3581.USD","LU0058720904.USD","BK4568","BK4566","LU2087621335.USD","ARVN","LU0289739699.SGD","IE00B7SZLL34.SGD","IE00B7SZL793.SGD","BK4123","LU0320765992.SGD","IE00B19Z3B42.SGD","LU2089984988.USD","IE00B19Z4B17.USD","LU1585245621.USD","IE0031619046.USD","BK4532","IE00B66KJ199.SGD","MG","IE00B3T34201.USD","IE00BSNM7G36.USD","IE0002270589.USD","LU0234570918.USD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1066053197.SGD","LU1571399168.USD","BK4007","IMVT","LU1430594728.SGD","BK4588","BK4139","BK4583","LU1839511570.USD","BK4585","GILD","BK4578"],"gpt_icon":0},{"id":"2520432854","title":"Immunovant Is Maintained at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2520432854","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520432854?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:42","pubTimestamp":1742467320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 06:42 ET (10:42 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"gpt_icon":0},{"id":"2520431052","title":"Immunovant price target lowered to $33 from $38 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2520431052","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520431052?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:15","pubTimestamp":1742465726,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Immunovant (IMVT) to $33 from $38 and keeps a Buy rating on the shares after yesterday’s topline data updat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-lowered-to-33-from-38-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-lowered-to-33-from-38-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","BK4588","IMVT"],"gpt_icon":0},{"id":"2520157897","title":"Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520157897","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520157897?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 00:43","pubTimestamp":1742402580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2025 12:43 ET (16:43 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"gpt_icon":0},{"id":"2520578321","title":"Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2520578321","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520578321?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 00:39","pubTimestamp":1742402340,"startTime":"0","endTime":"0","summary":"Wednesday, Immunovant,Inc.  released topline results from its Phase 3 study of batoclimab in myasthenia gravis  and initial results from Period 1 of its Phase 2b study in chronic inflammatory demyelinating polyneuropathy .Immunovant is a member of theRoivant Sciences Ltd. family of companies.In the Phase 3 MG study, batoclimab met its primary endpoint of mean change from baseline in Myasthenia Gravis Activities of Daily Living  score in acetylcholine receptor antibody positive  participants.Participants entering the study and randomized to 680mg of batoclimab given weekly by subcutaneous injection achieved a 5.6-point improvement  in MG-ADL at Week 12.In comparison, those randomized to 340mg of batoclimab given weekly by subcutaneous injection achieved a 4.7-point improvement .Initial batoclimab data in 73 patients pooled across all cohorts for the run-in Period 1 of the Phase 2b CIDP study demonstrated a 1.8 point improvement in aINCAT  at Week 12.An 84% responder rate  was observed a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunovant-ditches-seeking-fda-approval-163900373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","BK4139","IE00B66KJ199.SGD","BK4007","BK4123","IE0031619046.USD","MG","BK4588","IMVT","ROIV","BK4585","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2520157655","title":"Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2520157655","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520157655?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 00:30","pubTimestamp":1742401847,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovants-batoclimab-shows-impressive-efficacy-in-mg-says-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovants-batoclimab-shows-impressive-efficacy-in-mg-says-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MG","BK4588","IE00B7SZL793.SGD","BK4585","BK4123","IMVT","IE00B19Z4B17.USD","IE0031619046.USD","BK4139","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2520133847","title":"Immunovant Shares Down 5.2% After Late-Stage Data for Its Experimental Muscle Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2520133847","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520133847?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 21:32","pubTimestamp":1742391148,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q20QQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","IMVT","BK4139"],"gpt_icon":0},{"id":"2520183241","title":"Roivant says Immunovant announces results from Phase 3 study of batoclimab in MG","url":"https://stock-news.laohu8.com/highlight/detail?id=2520183241","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520183241?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:55","pubTimestamp":1742385322,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CI...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-says-immunovant-announces-results-from-phase-3-study-of-batoclimab-in-mg?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-says-immunovant-announces-results-from-phase-3-study-of-batoclimab-in-mg?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B7SZL793.SGD","BK4139","IE00B66KJ199.SGD","BK4123","IE0031619046.USD","MG","BK4588","IMVT","BK4585","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2520900762","title":"Immunovant's muscle disorder treatment meets main goal in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2520900762","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520900762?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:52","pubTimestamp":1742385172,"startTime":"0","endTime":"0","summary":"Immunovant's muscle disorder treatment meets main goal in late-stage trialMarch 19  - Immunovant IMVT.O said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nL4N3Q20ZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","IMVT"],"gpt_icon":0},{"id":"2520907057","title":"Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (Mg) and Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2520907057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520907057?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:45","pubTimestamp":1742384700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA5NVVDC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","IMVT","BK4139"],"gpt_icon":0},{"id":"2517945602","title":"Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2517945602","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517945602?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 01:29","pubTimestamp":1741109361,"startTime":"0","endTime":"0","summary":"Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2025/03/Stock-biohavenapp-01-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/03/Stock-biohavenapp-01-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/biohaven-stock-two-day-fall-bipolar-mania-igg-degrader/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU0320765992.SGD","BHVN","LU0889565916.HKD","LU0109394709.USD","IMVT","ARGX","BK4588","BK4139","LU1093756325.SGD","LU1093756168.USD","BK4585","BK4505"],"gpt_icon":0},{"id":"2516380946","title":"Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516380946","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516380946?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:50","pubTimestamp":1741006215,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Akero Therapeutics (AKRO – Research Report), Immunov...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-akero-therapeutics-akro-immunovant-imvt-and-4d-molecular-therapeutics-fdmt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-akero-therapeutics-akro-immunovant-imvt-and-4d-molecular-therapeutics-fdmt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKRO","HCSG","BK4139","BK4505","BK4137","BK4585","IMVT","FDMT","BK4588"],"gpt_icon":0},{"id":"2516680631","title":"Jefferies Initiates Immunovant at Hold With $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680631","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680631?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:15","pubTimestamp":1741004118,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) has an average rating of buy and mean price target of $46, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMVT"],"gpt_icon":0},{"id":"2516854520","title":"Immunovant initiated with a Hold at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2516854520","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516854520?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 01:10","pubTimestamp":1740935410,"startTime":"0","endTime":"0","summary":"Jefferies initiated coverage of Immunovant (IMVT) with a Hold rating and $20 price target The firm sees “significant value” for the second generati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-initiated-with-a-hold-at-jefferies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-initiated-with-a-hold-at-jefferies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4585","IMVT"],"gpt_icon":0},{"id":"2513754763","title":"Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2513754763","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513754763?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 02:33","pubTimestamp":1740335594,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Immunovant, Inc.  stands against the other oversold pharma stocks to buy according to analysts.On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity drugs. She believed the industry may not underperform this year, at least in the first half. However, there are still several questions surrounding the performance of obesity drugs, as major players in the domain have exhibited contrasting previous year performance.Angelica Peebles, CNBC’s Health and Pharma reporter, sat with Eli Lilly’s Chief Scientific Officer to talk about the weight loss sector. From the conversation, she reported that the domain poses opportunity for drugs that are easier to use, such as pills, and medicines that make people los","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunovant-inc-imvt-most-oversold-183314891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0170899867.USD","TSYW.SI","MNQmain","BK4139",".IXIC","PSQ","USAW.SI","USJW.SI","BK4585","BK4566","TQQQ","BK4588","SQQQ","NQmain","BK4187","QLD","BK4550","GD","IMVT","BK4516","NVIW.SI","QID"],"gpt_icon":1},{"id":"2513522118","title":"Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2513522118","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513522118?lang=en_us&edition=full_marsco","pubTime":"2025-02-22 13:53","pubTimestamp":1740203583,"startTime":"0","endTime":"0","summary":"We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Immunovant, Inc.  stands against the other oversold healthcare stocks.Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022. The healthcare sector accounted for around 17.6% of the US economy in 2023, reflecting a 17.4% rise from 2022. The two primary drivers of this growth are the rise in private health insurance and Medicare.READ ALSO:10 Best Performing Healthcare Stocks So Far in 2025and10 Most Undervalued Small-Cap Stocks To Invest In.What Could Trump’s Tariffs Mean for the Healthcare Industry. Delving deeper into the industry dynamics, Rizzuto termed the obesity space and, more broadly, the cardiometabolic domain as the single largest value-creation opportunity in the industry’","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunovant-inc-imvt-most-oversold-055303472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","TQQQ","TSYW.SI","GD","HCSG","IMVT","BK4588","BK4566","BK4585","MNQmain","BK4137","PSQ","BK4550","NVIW.SI","QLD","LU0170899867.USD","SQQQ","NQmain","BK4187","USJW.SI","BK4139","USAW.SI","QID","BK4516"],"gpt_icon":1},{"id":"2513262556","title":"Stifel Nicolaus Remains a Buy on Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513262556","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513262556?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 20:39","pubTimestamp":1740141571,"startTime":"0","endTime":"0","summary":"In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Immunovant (IMVT – Research Report), with a price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-immunovant-imvt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-immunovant-imvt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","IMVT","CFA","SF","BK4585","BK4588","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":-0.0457},{"period":"1month","weight":-0.0501},{"period":"3month","weight":-0.2327},{"period":"6month","weight":-0.3294},{"period":"1year","weight":-0.4222},{"period":"ytd","weight":-0.2414}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.099433},{"month":2,"riseRate":0,"avgChangeRate":-0.149849},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.048855},{"month":4,"riseRate":0.4,"avgChangeRate":-0.020694},{"month":5,"riseRate":0.4,"avgChangeRate":0.099229},{"month":6,"riseRate":0.2,"avgChangeRate":-0.098266},{"month":7,"riseRate":0.5,"avgChangeRate":0.046357},{"month":8,"riseRate":0.666667,"avgChangeRate":0.108139},{"month":9,"riseRate":0.833333,"avgChangeRate":0.124733},{"month":10,"riseRate":0.666667,"avgChangeRate":0.178851},{"month":11,"riseRate":0.666667,"avgChangeRate":0.072037},{"month":12,"riseRate":0.666667,"avgChangeRate":0.145522}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction